Cowen Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall St muted after Fed Chair Warsh's speech; AI rally cools
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil drifts lower as Hormuz flows balance slow progress in Iran diplomacy
- Dollar climbs after Warsh comments, poised for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- BioNTech ends colorectal cancer mRNA therapy trial early
Cantor Fitzgerald Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Hold
July 24, 2015 9:14 AM EDTCantor Fitzgerald downgraded Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) from Buy to Hold with a price target of $2.00 (from $4.00).
Analyst Mara Goldstein commented, "We are downgrading shares of Sunesis to HOLD from BUY based on the disappointing FDA guidance that will require... More
Roth Capital Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Sell, $1 PT
July 24, 2015 7:32 AM EDTRoth Capital downgraded Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) from Buy to Sell with a price target of $1.00 (from $5.50).
Analyst Joseph Pantginis commented, "Sunesis provided the much anticipated regulatory updates from both the FDA and EMA with mixed results, though we believe the... More
Sunesis Pharmaceuticals (SNSS) Issues Update on Meetings with EMA, FDA Over Vosaroxin in AML
July 23, 2015 4:22 PM EDTSunesis Pharmaceuticals (NASDAQ: SNSS) announced regulatory updates from its interactions with the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) regarding a potential path toward marketing authorization for vosaroxin as a treatment for acute myeloid leukemia (AML) in Europe and the United States.
With respect to Europe, the company recently met separately with the Rapporteur (United Kingdom) and Co-Rapporteur (Netherlands) assigned to provide advice and guide the company through the Marketing Authorization Application (MAA) process. Based on these substantive discussions, the company was encouraged to proceed with an MAA... More
